Hemostats Market

Hemostats Market by Type (Thrombin, Oxidised Regenerated Cellulose, Combination, Gelatin, Collagen), Application (Orthopedic Surgery, General Surgery, Gynecological), Formulation (Sponge, Powder, Matrix & Gel, Sheets & Pads) - Global Forecast to 2027

Report Code: MD 4093 Jul, 2021, by marketsandmarkets.com

The global hemostats market in terms of revenue was estimated to be worth $2.8 billion in 2022 and is poised to reach $3.7 billion by 2027, growing at a CAGR of 6.1% from 2022 to 2027. The current edition of the report includes pricing analysis, value chain analysis, supply chain analysis, ecosystem analysis, trade analysis, technology analysis, regulatory landscape analysis, patent analysis, and Porter's five forces analysis in the market overview chapter. This edition of the report also covers the product and geographical footprint of key players in the competitive landscape chapter. The growing geriatric population and concurrently rising demand for surgeries are driving the growth of this market.

Hemostats Market

To know about the assumptions considered for the study, Request for Free Sample Report

Hemostats Market Dynamics

Drivers: Increasing R&D Focus

The global hemostats market is witnessing a significant rise in the launch of new and advanced products globally. Vendors across the globe are relying on organic growth strategies to efficiently address end-user requirements and demands. As a result, a significant share of their capital investments is being diverted to R&D. This is an important trend in this market as new products with high efficacy and success rates gain rapid adoption among end users. As a result, product launches and innovations in products have become key strategies to gain a competitive edge in this market.

Over the last few decades, a continuous rise in R&D investments has been observed, especially among established players. This has led to the development of innovative hemostats, including hemostats, for various applications. B. Braun invested USD 422.4 million in R&D in fiscal 2020, a 3.3% increase over fiscal 2019. Similarly, in 2020, Baxter International will invest approximately USD 521 million in R&D.

Restraints: highly consolidated market

The top players in this market are large and well-established and enjoy a high degree of brand loyalty. New entrants in this market must compete with existing players and differentiate themselves with innovative product offerings. The high degree of consolidation acts as a major entry barrier for new entrants and is expected to restrict investments and the growth potential of this market. The requirement for high-capital investments and the high cost of R&D and manufacturing are also discouraging new entrants from entering this market.

Opportunities: Emerging Markets

The number of hospitals and surgical centres is increasing in both developed and emerging countries. The demand for surgical equipment (including medical devices such as hemostats) is high in these newly established surgical centres and hospitals, owing to the increasing patient population base. For instance, in October 2020, the Prime Minister of the UK announced plans to invest USD 4.3 billion in 40 hospitals and certain schemes for future funding for 48 hospitals by 2030. In addition, in March 2021, Steward Health Care announced plans to construct a new hospital in Washington County. The significant growth in the number of hospitals and surgical centres is expected to support the growth of the hemostats market, as these are key end users of the hemostats market.

Over the last few decades, countries such as India and Malaysia have emerged as hubs for medical tourism. This is because the cost of medical procedures in these emerging countries is significantly lower as compared to developed countries such as the US, Germany, France, and the UK. Also, the presence of skilled surgeons and the availability of well-equipped surgical care facilities across private hospital chains are driving the number of medical tourists travelling to these countries for treatment.

Challenges: Dearth of skilled personnel for the effective use of hemostatic products

Skilled professionals are required to handle hemostats as the improper closure of arteries after surgical procedures may lead to continuous bleeding or cause ischemia. Some devices even require several steps in sequence while using them. Based on the current scenario, the American College of Cardiology estimates a shortage of 21% of cardiac surgeons by 2025 in the US (source: American Heart Association).

Currently, the lack of skilled surgeons, both in developed and developing economies, is one of the major factors limiting the adoption of these products. For instance, the Association of American Medical Colleges (AAMC) projects a shortage of about 122,000 physicians by 2032 in the US. Of these, a shortage of 12,000 medical specialists, 23,400 surgeons, and 39,100 other specialists such as neurologists and radiologists is expected to occur by 2032.

The technology landscape and application areas of hemostats products are changing rapidly, owing to technological advancements in this field. This necessitates physicians and other healthcare providers to acquire the necessary skills to apply advanced hemostats products such as hemostats, bone graft substitutes, surgical sealants, and adhesives effectively. Therefore, surgeons and physicians in hospitals and clinics are reluctant to use advanced surgical products for wound closure.

Hemostats Market Ecosystem

Hemostats Market Ecosystem

In 2020, the thrombin-based hemostats segment accounted for the largest share of the hemostats market, by product type.

By type, the global market is segmented into thrombin-based hemostats, oxidised and regenerated cellulose-based hemostats, combination hemostats, gelatin-based hemostats, and collagen-based hemostats. In 2020, the thrombin-based hemostats segment accounted for the largest share of the global market. The advantages associated with the use of thrombin-based hemostats will boost market growth.

In 2020, Matrix and gel hemostats dominated the hemostats market.

On the basis of formulation, the global market is broadly segmented into matrix and gel hemostats, sheet and pad hemostats, sponge hemostats, and powder hemostats. In 2020, the matrix and gel hemostats segment accounted for the largest share of the global market. The market's growth can be attributed to the growing acceptance of these formulations by end users.

Orthopedic surgery accounted for the largest share of the hemostasis market in 2020.

Based on application, the market is segmented into neurological surgery, cardiovascular surgery, general surgery, orthopaedic surgery, gynaecological surgery, reconstructive surgery, and other surgeries (urological, thoracic, and ENT surgeries). In 2020, the orthopaedic surgery segment accounted for the largest share of the global marketery, general surgery, orthopaedic surgery, gynaecological surgery, reconstructive surgery, and other surgeries (urological, thoracic, and ENT surgeries). In 2020, the orthopaedic surgery segment accounted for the largest share of the global market. The growing geriatric population, the increasing incidence of sports injuries, and the growing prevalence of lifestyle disorders (such as arthritis, osteoporosis, and obesity) are some of the major factors responsible for the growing number of orthopaedic surgeries performed globally, which will boost market growth.

China is anticipated to account for the largest share of the APAC hemostats market.

Based on the APAC region, the Hemostats are divided into Japan, China, India, South Korea, Australia, New Zealand, Malaysia, Indonesia, Singapore, and the Rest of Asia Pacific. China is expected to account for the largest share of hemostats. The favourable government initiatives and improved access to healthcare, the availability of inpatient and outpatient care for chronic diseases, and the rising number of surgical procedures are the major factors supporting the growth of the hemostat industry in China.

North America dominates the global hemostats market.

Based on the region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. North America is expected to dominate the hemostats market. Growth in the North American market is mainly driven by growing demand for hemostats during surgeries and strong healthcare infrastructure.

Hemostats Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The global hemostat market is consolidated. The companies offer hemostats for various applications, such as Ethicon (US),  Baxter International (US), and Pfizer (US).

Hemostats Market Report Scope

Report Metric

Details

Market Revenue in 2022

$2.8 billion

Estimated Value by 2027

$3.7 billion

Growth Rate

poised to grow at a CAGR of 6.1%

Largest Share Segments

Thrombin-based Hemostats, Matrix and Gel Hemostats & Orthopedic Surgery

Market Report Segmentation

Type, Formulation, Application & Region

Market Drivers

  • Growing volume of surgical procedures performed
  • Rising focus on R&D
  • Increasing incidence of sports-related injuries and spinal ailments
  • Rising focus on effective blood loss management in patients during surgeries

Market Opportunities

  • Growth in the number of hospitals & surgical centers
  • Growing adoption of advanced hemostats in emerging markets

Geographies covered

North America, Europe, APAC, MEA, and Latin America

This research report categorizes the Hemostats market into the following segments and subsegments:

By Type

  • Thrombin-Based Hemostats
  • Oxidized Regenerated Cellulose-Based Hemostats
  • Combination Hemostats
  • Gelatin-Based Hemostats
  • Collagen-Based Hemostats

By Formulation

  • Matrix & Gel Hemostats
  • Sheet & Pad Hemostats
  • Sponge Hemostats
  • Powder Hemostats

By Application

  • Orthopedic Surgery
  • General Surgery
  • Neurological Surgery
  • Cardiovascular Surgery
  • Reconstructive Surgery
  • Gynecological Surgery
  • Other Surgeries

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Russia
    • Switzerland
    • Belgium
    • RoE
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • Singapore
    • New Zealand
    • South Korea
    • Indonesia
    • Malaysia
    • RoAPAC
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa

Recent Developments

  • In 2022, Dophin Suture launched hemostatic products under a new vertical Dolphin Hemostats.
  • In 2021, Baxter acquired PerClot Polysaccharide Hemostatic System to Expand Advanced Surgery Portfolio
  • In 2020, Teleflex acquired Z-Medica, LLC (US), a privately held medical device company that manufactures and sells hemostatic (hemorrhage control) products marketed under the QuikClot Combat Gauze and QuikClot Control+ brand names to enhance its product portfolio.
  • In 2020, Baxter announced 510(k) clearance from the US FDA for Peri-Strips Dry with Veritas Collagen Matrix product with Secure Grip. The product helps in mitigating bleeding during bariatric surgeries and other surgical procedures.

Frequently Asked Questions (FAQs):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 27)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS AND EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
           TABLE 1 EXCHANGE RATES UTILIZED FOR THE CONVERSION TO USD
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 33)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Secondary sources
           2.1.2 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.2.1 Key data from primary sources
                    2.1.2.2 Key industry insights
                    2.1.2.3 Breakdown of primary interviews: By company type, designation, and region
    2.2 MARKET SIZE ESTIMATION
           FIGURE 3 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 4 REVENUE SHARE ANALYSIS ILLUSTRATION—BAXTER INTERNATIONAL, INC.
           FIGURE 5 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
           FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           FIGURE 7 TOP-DOWN APPROACH
    2.3 MARKET BREAKDOWN & DATA TRIANGULATION
           FIGURE 8 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ANALYSIS
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 LIMITATIONS
           2.6.1 METHODOLOGY-RELATED LIMITATIONS
    2.7 RISK ASSESSMENT
           TABLE 2 RISK ASSESSMENT: HEMOSTATS MARKET
    2.8 COVID-19 HEALTH ASSESSMENT
    2.9 COVID-19 ECONOMIC ASSESSMENT
    2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
            FIGURE 9 CRITERIA IMPACTING THE GLOBAL ECONOMY
            FIGURE 10 RECOVERY SCENARIO OF THE GLOBAL ECONOMY

3 EXECUTIVE SUMMARY (Page No. - 49)
    FIGURE 11 HEMOSTATS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 12 GLOBAL MARKET, BY FORMULATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 13 GLOBAL MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 14 GLOBAL MARKET, BY REGION, 2021 VS. 2026 (USD MILLION)

4 PREMIUM INSIGHTS (Page No. - 52)
    4.1 HEMOSTATS MARKET OVERVIEW
           FIGURE 15 NEED TO MANAGE BLOOD LOSS IN PATIENTS DURING SURGICAL PROCEDURES TO DRIVE MARKET GROWTH
    4.2 ASIA PACIFIC: MARKET, BY FORMULATION & COUNTRY (2020)
           FIGURE 16 MATRIX & GEL HEMOSTATS SEGMENT ACCOUNTED FOR THE LARGEST MARKET SHARE IN 2020
    4.3 HEMOSTATS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
           FIGURE 17 INDIA TO REGISTER THE HIGHEST REVENUE GROWTH DURING THE FORECAST PERIOD
    4.4 GLOBAL MARKET, BY TYPE (2021–2026)
           FIGURE 18 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS WILL CONTINUE TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION
    5.2 MARKET DYNAMICS
           FIGURE 19 HEMOSTATS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Growing volume of surgical procedures performed
                               TABLE 3 UK: NUMBER OF CARDIAC SURGICAL PROCEDURES, 2010-2019
                    5.2.1.2 Rising focus on R&D
                    5.2.1.3 Increasing incidence of sports-related injuries and spinal ailments
                    5.2.1.4 Rising focus on effective blood loss management in patients during surgeries
           5.2.2 OPPORTUNITIES
                    5.2.2.1 Growth in the number of hospitals & surgical centers
                    5.2.2.2 Growing adoption of advanced hemostats in emerging markets
                               TABLE 4 COST OF SURGICAL PROCEDURES: US VS. INDIA (USD)
           5.2.3 RESTRAINTS
                    5.2.3.1 Side effects and allergic reactions associated with hemostats
                    5.2.3.2 Highly consolidated market
           5.2.4 CHALLENGES
                    5.2.4.1 Dearth of skilled personnel for the effective use of hemostats
                    5.2.4.2 Stringent regulatory framework
                    5.2.4.3 High cost of hemostats
    5.3 COVID-19 IMPACT ANALYSIS
    5.4 RANGES/SCENARIOS
           FIGURE 20 PESSIMISTIC SCENARIO
           FIGURE 21 OPTIMISTIC SCENARIO
           FIGURE 22 REALISTIC SCENARIO
    5.5 REGULATORY ANALYSIS
           TABLE 5 INDICATIVE LIST OF REGULATORY AUTHORITIES GOVERNING HEMOSTATS
           5.5.1 NORTH AMERICA
                    5.5.1.1 US
                               TABLE 6 CLASSIFICATION OF MEDICAL DEVICES BY THE US FDA
                               FIGURE 23 PREMARKET NOTIFICATION: 510(K) APPROVAL FOR MEDICAL DEVICES
                    5.5.1.2 Canada
                               FIGURE 24 APPROVAL PROCESS FOR CLASS III MEDICAL DEVICES IN CANADA
           5.5.2 EUROPE
                    FIGURE 25 CE APPROVAL PROCESS IN EUROPE FOR HEMOSTATS
           5.5.3 ASIA PACIFIC
                    5.5.3.1 Japan
                               TABLE 7 CLASSIFICATION OF MEDICAL DEVICES AND THE REVIEWING BODY IN JAPAN
                    5.5.3.2 China
                               TABLE 8 NMPA MEDICAL DEVICES CLASSIFICATION
                    5.5.3.3 India
                               TABLE 9 CLASSIFICATION OF HEMOSTATS IN INDIA
    5.6 PORTER’S FIVE FORCES ANALYSIS
           TABLE 10 PORTER’S FIVE FORCES ANALYSIS
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 THREAT OF SUBSTITUTES
           5.6.3 BARGAINING POWER OF SUPPLIERS
           5.6.4 BARGAINING POWER OF BUYERS
           5.6.5 INTENSITY OF COMPETITIVE RIVALRY
    5.7 TECHNOLOGY ANALYSIS
    5.8 VALUE CHAIN ANALYSIS
            FIGURE 26 VALUE CHAIN ANALYSIS: MAXIMUM VALUE IS ADDED DURING THE MANUFACTURING PHASE
    5.9 SUPPLY CHAIN ANALYSIS
            FIGURE 27 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES
    5.10 PATENT ANALYSIS
           5.10.1 PATENT GRANTED TRENDS FOR HEMOSTATS
                     FIGURE 28 PATENT GRANTED TRENDS, JANUARY 2011–JULY 2021
           5.10.2 JURISDICTION AND TOP APPLICANT ANALYSIS
                     FIGURE 29 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR HEMOSTAT PATENTS, JANUARY 2011 TO JULY 2021
           5.10.3 PUBLICATION TRENDS FOR HEMOSTATS
    5.11 TRADE ANALYSIS
           5.11.1 TRADE ANALYSIS FOR HEMOSTATS
                    TABLE 11 IMPORT DATA FOR HEMOSTATS, BY COUNTRY, 2016–2020 (USD MILLION)
                    TABLE 12 EXPORT DATA FOR HEMOSTATS, BY COUNTRY, 2016–2020 (USD MILLION)
    5.12 PRICING ANALYSIS
            TABLE 13 AVERAGE SELLING PRICE FOR HEMOSTATS
    5.13 ECOSYSTEM ANALYSIS
            FIGURE 30 GLOBAL MARKET: ECOSYSTEM ANALYSIS
           5.13.1 ROLE IN THE ECOSYSTEM
                     FIGURE 31 KEY PLAYERS
    5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
           5.14.1 REVENUE SHIFT & REVENUE POCKETS FOR HEMOSTAT MANUFACTURERS

6 HEMOSTATS MARKET, BY TYPE (Page No. - 81)
    6.1 INTRODUCTION
           TABLE 14 HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
           TABLE 15 GLOBAL MARKET, BY TYPE, 2020–2026 (USD MILLION)
    6.2 THROMBIN-BASED HEMOSTATS
           6.2.1 DEVELOPMENTS IN RECOMBINANT THROMBIN PRODUCTS TO SUPPORT THE GROWTH OF THIS MARKET
                    TABLE 16 MAJOR PRODUCTS IN THE THROMBIN-BASED MARKET
                    TABLE 17 THROMBIN-BASED MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 18 THROMBIN-BASED MARKET, BY REGION, 2020–2026 (USD MILLION)
    6.3 OXIDIZED REGENERATED CELLULOSE-BASED HEMOSTATS
           6.3.1 VENDORS ARE EXPANDING THE AVAILABILITY OF THEIR ORC-BASED HEMOSTATIC AGENTS ACROSS UNTAPPED MARKETS IN THE APAC
                    TABLE 19 MAJOR PRODUCTS IN THE OXIDIZED REGENERATED CELLULOSE-BASED MARKET
                    TABLE 20 OXIDIZED REGENERATED CELLULOSE-BASED MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 21 OXIDIZED REGENERATED CELLULOSE-BASED MARKET, BY REGION, 2020–2026 (USD MILLION)
    6.4 COMBINATION HEMOSTATS
           6.4.1 ADVANCEMENTS IN COMBINATION MATERIALS ARE SUPPORTING THE GROWTH OF THIS SEGMENT
                    TABLE 22 MAJOR PRODUCTS IN THE COMBINATION MARKET
                    TABLE 23 COMBINATION MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 24 COMBINATION MARKET, BY REGION, 2020–2026 (USD MILLION)
    6.5 GELATIN-BASED HEMOSTATS
           6.5.1 GELATIN-BASED HEMOSTATS OFFER HIGH ELASTICITY
                    TABLE 25 MAJOR PRODUCTS IN THE GELATIN-BASED MARKET
                    TABLE 26 GELATIN-BASED MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 27 GELATIN-BASED MARKET, BY REGION, 2020–2026 (USD MILLION)
    6.6 COLLAGEN-BASED HEMOSTATS
           6.6.1 LOW COST AND REDUCED RISK OF DISEASE TRANSMISSION ARE PROMOTING THE ADOPTION OF COLLAGEN-BASED HEMOSTATS
                    TABLE 28 MAJOR PRODUCTS IN THE COLLAGEN-BASED MARKET
                    TABLE 29 COLLAGEN-BASED MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 30 COLLAGEN-BASED MARKET, BY REGION, 2020–2026 (USD MILLION)

7 HEMOSTATS MARKET, BY FORMULATION (Page No. - 91)
    7.1 INTRODUCTION
           TABLE 31 HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
           TABLE 32 GLOBAL MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
    7.2 MATRIX & GEL HEMOSTATS
           7.2.1 MATRIX & GEL HEMOSTATS ENHANCE PLATELET AGGREGATION
                    TABLE 33 MATRIX & GEL HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 34 MATRIX & GEL MARKET, BY REGION, 2020–2026 (USD MILLION)
    7.3 SHEET & PAD HEMOSTATS
           7.3.1 SHEET & PAD HEMOSTATS CAN BE CUT INTO ANY SHAPE OR SIZE, DEPENDING ON THE SURGICAL WOUND
                    TABLE 35 SHEET & PAD HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 36 SHEET & PAD MARKET, BY REGION, 2020–2026 (USD MILLION)
    7.4 SPONGE HEMOSTATS
           7.4.1 SPONGE HEMOSTATS TO WITNESS THE HIGHEST GROWTH DURING THE FORECAST PERIOD
                    TABLE 37 SPONGE HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 38 SPONGE MARKET, BY REGION, 2020–2026 (USD MILLION)
    7.5 POWDER HEMOSTATS
           7.5.1 POWDER FORMULATIONS CAN BE SPRAYED DIRECTLY ON THE WOUND
                    TABLE 39 POWDER HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 40 POWDER MARKET, BY REGION, 2020–2026 (USD MILLION)

8 HEMOSTATS MARKET, BY APPLICATION (Page No. - 97)
    8.1 INTRODUCTION
           TABLE 41 HEMOSTATS MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
           TABLE 42 GLOBAL MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
    8.2 ORTHOPEDIC SURGERY
           8.2.1 ORTHOPEDIC SURGERY IS THE LARGEST APPLICATION SEGMENT FOR HEMOSTATS
                    TABLE 43 MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 44 GLOBAL MARKET FOR ORTHOPEDIC SURGERY, BY REGION, 2020–2026 (USD MILLION)
    8.3 GENERAL SURGERY
           8.3.1 INCREASING NUMBER OF HERNIA REPAIR PROCEDURES TO DRIVE THE GROWTH OF THIS SEGMENT
                    TABLE 45 HEMOSTATS MARKET FOR GENERAL SURGERY, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 46 GLOBAL MARKET FOR GENERAL SURGERY, BY REGION, 2020–2026 (USD MILLION)
    8.4 NEUROLOGICAL SURGERY
           8.4.1 GROWING PREVALENCE OF NEUROLOGICAL DISORDERS TO DRIVE MARKET GROWTH
                    TABLE 47 HEMOSTATS MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 48 GLOBAL MARKET FOR NEUROLOGICAL SURGERY, BY REGION, 2020–2026 (USD MILLION)
    8.5 CARDIOVASCULAR SURGERY
           8.5.1 RISING PREVALENCE OF CVD TO DRIVE THE ADOPTION OF HEMOSTATS
                    TABLE 49 HEMOSTATS MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 50 GLOBAL MARKET FOR CARDIOVASCULAR SURGERY, BY REGION, 2020–2026 (USD MILLION)
    8.6 RECONSTRUCTIVE SURGERY
           8.6.1 GROWING NUMBER OF FACIAL COSMETIC SURGERIES TO SUPPORT MARKET GROWTH
                    TABLE 51 HEMOSTATS MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 52 GLOBAL MARKET FOR RECONSTRUCTIVE SURGERY, BY REGION, 2020–2026 (USD MILLION)
    8.7 GYNECOLOGICAL SURGERY
           8.7.1 HEMOSTATS ARE COMMONLY USED IN C-SECTION PROCEDURES TO CONTROL SURGICAL BLEEDING AND RELATED COMPLICATIONS
                    TABLE 53 C-SECTION SURGERIES PER 1,000 BIRTHS (2018)
                    TABLE 54 HEMOSTATS ARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2016–2019 (USD MILLION)
                    TABLE 55 GLOBAL MARKET FOR GYNECOLOGICAL SURGERY, BY REGION, 2020–2026 (USD MILLION)
    8.8 OTHER SURGERIES
           TABLE 56 HEMOSTATS ARKET FOR OTHER SURGERIES, BY REGION, 2016–2019 (USD MILLION)
           TABLE 57 GLOBAL MARKET FOR OTHER SURGERIES, BY REGION, 2020–2026 (USD MILLION)

9 HEMOSTATS MARKET, BY REGION (Page No. - 109)
    9.1 INTRODUCTION
           TABLE 58 HEMOSTATS MARKET, BY REGION, 2016–2019 (USD MILLION)
           TABLE 59 GLOBAL MARKET, BY REGION, 2020–2026 (USD MILLION)
    9.2 NORTH AMERICA
           FIGURE 32 NORTH AMERICA: HEMOSTATS MARKET SNAPSHOT
           TABLE 60 NORTH AMERICA: MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
           TABLE 61 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
           TABLE 62 NORTH AMERICA: MARKET, BY TYPE, 2016–2019 (USD MILLION)
           TABLE 63 NORTH AMERICA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           TABLE 64 NORTH AMERICA: HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
           TABLE 65 NORTH AMERICA: MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
           TABLE 66 NORTH AMERICA: MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
           TABLE 67 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
           9.2.1 US
                    9.2.1.1 The US dominates the North American hemostats market
                                TABLE 68 US: KEY MACROINDICATORS
                                TABLE 69 US: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 70 US: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.2.2 CANADA
                    9.2.2.1 Growing geriatric population and the increasing volume of surgeries to drive the demand for hemostats in Canada
                                TABLE 71 SURGICAL PROCEDURES PERFORMED IN CANADA, 2019
                                TABLE 72 CANADA: KEY MACROINDICATORS
                                TABLE 73 CANADA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 74 CANADA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
    9.3 EUROPE
           TABLE 75 EUROPE: MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
           TABLE 76 EUROPE: MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
           TABLE 77 EUROPE: MARKET, BY TYPE, 2016–2019 (USD MILLION)
           TABLE 78 EUROPE: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           TABLE 79 EUROPE: HEMOSTATS MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
           TABLE 80 EUROPE: MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
           TABLE 81 EUROPE: MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
           TABLE 82 EUROPE: MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
           9.3.1 GERMANY
                    9.3.1.1 High healthcare expenditure in Germany to favor market growth
                                TABLE 83 SURGICAL PROCEDURES PERFORMED IN GERMANY, 2019
                                TABLE 84 GERMANY: KEY MACROINDICATORS
                                TABLE 85 GERMANY: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 86 GERMANY: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.3.2 UK
                    9.3.2.1 Growing volume of hernia repair and cardiovascular surgeries in the UK to drive market growth
                                TABLE 87 SURGICAL PROCEDURES PERFORMED IN THE UK, 2019
                                TABLE 88 UK: KEY MACROINDICATORS
                                TABLE 89 UK: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 90 UK: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.3.3 FRANCE
                    9.3.3.1 Presence of a well-established healthcare system and growing geriatric population to propel market growth
                                TABLE 91 SURGICAL PROCEDURES PERFORMED IN FRANCE, 2019
                                TABLE 92 FRANCE: KEY MACROINDICATORS
                                TABLE 93 FRANCE: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 94 FRANCE: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.3.4 ITALY
                    9.3.4.1 Increasing volume of surgeries to drive the demand for hemostats in the country
                                TABLE 95 SURGICAL PROCEDURES PERFORMED IN ITALY, 2019
                                TABLE 96 ITALY: KEY MACROINDICATORS
                                TABLE 97 ITALY: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 98 ITALY: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.3.5 SPAIN
                    9.3.5.1 Growing healthcare budget and rising efforts for boosting the local manufacturing of medical products to drive market growth
                                TABLE 99 SURGICAL PROCEDURES PERFORMED IN SPAIN, 2019
                                TABLE 100 SPAIN: KEY MACROINDICATORS
                                TABLE 101 SPAIN: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 102 SPAIN: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.3.6 RUSSIA
                    9.3.6.1 Rising public healthcare expenditure to support market growth
                                TABLE 103 RUSSIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 104 RUSSIA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.3.7 SWITZERLAND
                    9.3.7.1 Increasing public health insurance coverage to drive the number of surgical procedures
                                TABLE 105 SURGICAL PROCEDURES PERFORMED IN SWITZERLAND, 2019
                                TABLE 106 SWITZERLAND: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 107 SWITZERLAND: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.3.8 BELGIUM
                    9.3.8.1 Increasing demand for value-based healthcare services to drive market growth
                                TABLE 108 SURGICAL PROCEDURES PERFORMED IN BELGIUM, 2019
                                TABLE 109 BELGIUM: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 110 BELGIUM: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.3.9 REST OF EUROPE
                    TABLE 111 ROE: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                    TABLE 112 ROE: MARKET, BY TYPE, 2020–2026 (USD MILLION)
    9.4 ASIA PACIFIC
           FIGURE 33 APAC: HEMOSTATS MARKET SNAPSHOT
           TABLE 113 ASIA PACIFIC: HEMOSTATS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
           TABLE 114 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
           TABLE 115 ASIA PACIFIC: MARKET, BY TYPE, 2016–2019 (USD MILLION)
           TABLE 116 ASIA PACIFIC: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           TABLE 117 ASIA PACIFIC: MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
           TABLE 118 ASIA PACIFIC: MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
           TABLE 119 ASIA PACIFIC: MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
           TABLE 120 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
           9.4.1 CHINA
                    9.4.1.1 Growing number of hospitals and healthcare policy reforms are driving the growth of the hemostats market
                                TABLE 121 CHINA: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 122 CHINA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.2 JAPAN
                    9.4.2.1 Strong healthcare system and rising geriatric population to support market growth in Japan
                                TABLE 123 JAPAN: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 124 JAPAN: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.3 INDIA
                    9.4.3.1 Rising healthcare awareness and favorable government support to propel market growth in India
                                TABLE 125 INDIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 126 INDIA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.4 AUSTRALIA
                    9.4.4.1 Rising prevalence of chronic diseases to drive market growth
                                TABLE 127 AUSTRALIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 128 AUSTRALIA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.5 SOUTH KOREA
                    9.4.5.1 Growing number of cosmetic surgeries to drive the demand for hemostats in South Korea
                                TABLE 129 SURGICAL PROCEDURES IN SOUTH KOREA, 2019
                                TABLE 130 SOUTH KOREA: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 131 SOUTH KOREA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.6 SINGAPORE
                    9.4.6.1 Government initiatives to promote the country’s healthcare services to support market growth
                                TABLE 132 SINGAPORE: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 133 SINGAPORE: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.7 NEW ZEALAND
                    9.4.7.1 Increasing number of bariatric surgeries to propel market growth
                                TABLE 134 NEW ZEALAND: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 135 NEW ZEALAND: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.8 INDONESIA
                    9.4.8.1 Indonesia offers lucrative growth opportunities for players in the hemostats market
                                TABLE 136 INDONESIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 137 INDONESIA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.9 MALAYSIA
                    9.4.9.1 Low healthcare costs, modern medical technology, and highly qualified doctors to favor market growth in the country
                                TABLE 138 MALAYSIA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 139 MALAYSIA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.4.10 REST OF ASIA PACIFIC
                     TABLE 140 ROAPAC: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                     TABLE 141 ROAPAC: MARKET, BY TYPE, 2020–2026 (USD MILLION)
    9.5 LATIN AMERICA
           TABLE 142 LATIN AMERICA: HEMOSTATS MARKET, BY COUNTRY, 2016–2019 (USD MILLION)
           TABLE 143 LATIN AMERICA: MARKET, BY COUNTRY, 2020–2026 (USD MILLION)
           TABLE 144 LATIN AMERICA: MARKET, BY TYPE, 2016–2019 (USD MILLION)
           TABLE 145 LATIN AMERICA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           TABLE 146 LATIN AMERICA: MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
           TABLE 147 LATIN AMERICA: MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
           TABLE 148 LATIN AMERICA: MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
           TABLE 149 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2026 (USD MILLION)
           9.5.1 BRAZIL
                    9.5.1.1 Brazil accounted for the largest share of the LATAM market in 2020
                                TABLE 150 BRAZIL: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 151 BRAZIL: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.5.2 MEXICO
                    9.5.2.1 Low-cost surgeries are driving medical tourism in Mexico
                                TABLE 152 MEXICO: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                                TABLE 153 MEXICO: MARKET, BY TYPE, 2020–2026 (USD MILLION)
           9.5.3 REST OF LATIN AMERICA
                    TABLE 154 REST OF LATIN AMERICA: MARKET, BY TYPE, 2016–2019 (USD MILLION)
                    TABLE 155 REST OF LATIN AMERICA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
    9.6 MIDDLE EAST & AFRICA
           9.6.1 MEA IS THE SMALLEST REGIONAL MARKET FOR HEMOSTATS
                    TABLE 156 MIDDLE EAST & AFRICA: HEMOSTATS MARKET, BY TYPE, 2016–2019 (USD MILLION)
                    TABLE 157 MIDDLE EAST & AFRICA: MARKET, BY TYPE, 2020–2026 (USD MILLION)
                    TABLE 158 MIDDLE EAST & AFRICA: MARKET, BY FORMULATION, 2016–2019 (USD MILLION)
                    TABLE 159 MIDDLE EAST & AFRICA: MARKET, BY FORMULATION, 2020–2026 (USD MILLION)
                    TABLE 160 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2016–2019 (USD MILLION)
                    TABLE 161 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2026 (USD MILLION)

10 COMPETITIVE LANDSCAPE (Page No. - 166)
     10.1 OVERVIEW
     10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
             TABLE 162 OVERVIEW OF STRATEGIES ADOPTED BY KEY HEMOSTAT PLAYERS
     10.3 REVENUE ANALYSIS
             FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN THE HEMOSTATS MARKET
     10.4 MARKET SHARE ANALYSIS
             FIGURE 35 GLOBAL MARKET SHARE ANALYSIS, 2020
             TABLE 163 GLOBAL MARKET: DEGREE OF COMPETITION
     10.5 COMPETITIVE LEADERSHIP MAPPING
             FIGURE 36 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
     10.6 COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS
             FIGURE 37 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES & START-UPS (2020)
     10.7 COMPANY FOOTPRINT
             TABLE 164 COMPANY FOOTPRINT
             TABLE 165 COMPANY TYPE FOOTPRINT
             TABLE 166 COMPANY REGIONAL FOOTPRINT
     10.8 COMPETITIVE SCENARIO
             10.8.1 DEALS
                       TABLE 167 KEY DEALS, JANUARY 2018– JUNE 2021
             10.8.2 PRODUCT LAUNCHES & APPROVALS
                       TABLE 168 KEY PRODUCT LAUNCHES & APPROVALS, JANUARY 2018– JUNE 2021
             10.8.3 OTHER DEVELOPMENTS
                       TABLE 169 OTHER DEVELOPMENTS, JANUARY 2018– JUNE 2021

11 COMPANY PROFILES (Page No. - 181)
     11.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             11.1.1 BECTON, DICKINSON & COMPANY (C. R. BARD)
                       TABLE 170 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW
                       FIGURE 38 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020)
             11.1.2 BAXTER INTERNATIONAL, INC.
                       TABLE 171 BAXTER INTERNATIONAL: BUSINESS OVERVIEW
                       FIGURE 39 BAXTER INTERNATIONAL: COMPANY SNAPSHOT (2020)
             11.1.3 TELEFLEX INCORPORATED
                       TABLE 172 TELEFLEX INCORPORATED: BUSINESS OVERVIEW
                       FIGURE 40 TELEFLEX INCORPORATED: COMPANY SNAPSHOT (2020)
             11.1.4 B. BRAUN MELSUNGEN AG
                       TABLE 173 B. BRAUN MELSUNGEN AG: BUSINESS OVERVIEW
                       FIGURE 41 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT (2020)
             11.1.5 JOHNSON & JOHNSON (ETHICON, INC.)
                       TABLE 174 JOHNSON & JOHNSON: BUSINESS OVERVIEW
                       FIGURE 42 JOHNSON & JOHNSON: COMPANY SNAPSHOT (2020)
             11.1.6 MEDTRONIC PLC
                       TABLE 175 MEDTRONIC PLC: BUSINESS OVERVIEW
                       FIGURE 43 MEDTRONIC PLC: COMPANY SNAPSHOT (2020)
             11.1.7 HEMOSTASIS, LLC
                       TABLE 176 HEMOSTASIS, LLC: BUSINESS OVERVIEW
             11.1.8 PFIZER INC.
                       TABLE 177 PFIZER INC.: BUSINESS OVERVIEW
                       FIGURE 44 PFIZER INC.: COMPANY SNAPSHOT (2020)
             11.1.9 STRYKER
                       TABLE 178 STRYKER CORPORATION: BUSINESS OVERVIEW
                       FIGURE 45 STRYKER: COMPANY SNAPSHOT (2020)
             11.1.10 CRYOLIFE, INC.
                        TABLE 179 CRYOLIFE, INC.: BUSINESS OVERVIEW
                        FIGURE 46 CRYOLIFE, INC.: COMPANY SNAPSHOT (2020)
             11.1.11 MARINE POLYMER TECHNOLOGIES
                        TABLE 180 MARINE POLYMER TECHNOLOGIES: BUSINESS OVERVIEW
             11.1.12 GELITA MEDICAL GMBH
                        TABLE 181 GELITA MEDICAL GMBH: BUSINESS OVERVIEW
             11.1.13 INTEGRA LIFESCIENCES HOLDINGS CORPORATION
                        TABLE 182 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: BUSINESS OVERVIEW
                        FIGURE 47 INTEGRA LIFESCIENCES HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
             11.1.14 ADVANCED MEDICAL SOLUTIONS GROUP PLC
                        TABLE 183 ADVANCED MEDICAL SOLUTIONS GROUP PLC: BUSINESS OVERVIEW
                        FIGURE 48 ADVANCED MEDICAL SOLUTIONS GROUP PLC: COMPANY SNAPSHOT (2020)
             11.1.15 BETATECH MEDICAL
                        TABLE 184 BETATECH MEDICAL: BUSINESS OVERVIEW
             11.1.16 MERIL LIFE SCIENCES PVT. LTD.
                        TABLE 185 MERIL LIFE SCIENCES PVT. LTD.: BUSINESS OVERVIEW
             11.1.17 SAMYANG HOLDINGS CORPORATION
                        TABLE 186 SAMYANG HOLDINGS CORPORATION: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     11.2 OTHER PLAYERS
             11.2.1 BIOM’UP
             11.2.2 BIOCER ENTWICKLUNGS-GMBH
             11.2.3 UNILENE
             11.2.4 KATSAN MEDICAL DEVICES
             11.2.5 TRICOL BIOMEDICAL INC.
             11.2.6 STARSIL HEMOSTAT
             11.2.7 3-D MATRIX MEDICAL TECHNOLOGY
             11.2.8 MEDTRADE PRODUCTS LIMITED
             11.2.9 ALTAYLAR MEDICAL

12 APPENDIX (Page No. - 223)
     12.1 DISCUSSION GUIDE
     12.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     12.3 AVAILABLE CUSTOMIZATIONS
     12.4 RELATED REPORTS
     12.5 AUTHOR DETAILS

The study involved four major activities in estimating the current size of the Hemostats market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of the segments and subsegments.

Secondary Research

In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

Primary Research

Extensive primary research was conducted after acquiring knowledge about the global market scenario through secondary research. Primary interviews were conducted from both the demand (Medical Practitioners, Hospital Directors) and supply sides (Marketing Managers, Regional/Area Sales Managers, Product Managers/Technology Experts, Import/Export Heads, Distribution Channel Partners).

The following is a breakdown of the primary respondents:

Hemostats Market Size

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the Hemostats market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and markets have been identified through extensive secondary research
  • The industry’s supply chain and market size, in terms of value, have been determined through primary and secondary research processes
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources

Data Triangulation

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the Hemostatsindustry.

Report Objectives

  • To define, describe, and forecast the global Hemostats market based on type, formulation, application, and region
  • To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific, Latin America  and Middle East & Africa
  • To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
  • To track and analyze competitive developments such as acquisitions, new product launches, expansions, regulatory approvals, and agreements in the Hemostats market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:

  • Product Analysis: Product matrix, which gives a detailed comparison of the product portfolios of each company
  • Geographic Analysis: Further breakdown of the hemostats market into specific countries/regions in the Rest of Europe, Rest of Asia Pacific, Rest of Latin America and the Rest of the World
Report Code
MD 4093
Published ON
Jul, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Hemostats Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2023 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback